Drugs / ALB 109564(a)
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00724100 | Sep 2008 → Dec 2010 | cancer | Albany Molecular Research, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALB 109564(a) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00724100 ↗ |
| Known as | 12´-methylthiovinblastine dihydrochloride | “ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)” NCT00724100 ↗ |
| Action | Inhibit | “a tubulin inhibitor” NCT00724100 ↗ |
| Route | Intravenous | “administered by intravenous infusion” NCT00724100 ↗ |